Skip to main content

Table 6 Results of the scenario analysis (favorable and intermediate cytogenetic risk subgroup)

From: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Parameter

GO + DA (a)

DA (b)

Difference

(a-b)

ICER,

a vs b (€)

Total costs (€)

166,615

167,414

-799

-

Life Years (LYs)

7.61

6.41

1.20

-664

QALYs

5.57

4.67

0.90

-888

  1. DA = daunorubicin and cytarabine, GO = gemtuzumab ozogamicin. ICER = incremental cost-effectiveness ratio, LY = life year, QALY = quality adjusted life year
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us